233 related articles for article (PubMed ID: 15303839)
1. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
[TBL] [Abstract][Full Text] [Related]
2. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
Bowman MJ; Chmielewski J
Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
4. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
5. Development of low molecular weight HIV-1 protease dimerization inhibitors.
Hwang YS; Chmielewski J
J Med Chem; 2005 Mar; 48(6):2239-42. PubMed ID: 15771466
[TBL] [Abstract][Full Text] [Related]
6. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
7. Sidechain-linked inhibitors of HIV-1 protease dimerization.
Bowman MJ; Chmielewski J
Bioorg Med Chem; 2009 Feb; 17(3):967-76. PubMed ID: 18337105
[TBL] [Abstract][Full Text] [Related]
8. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
Perryman AL; Lin JH; Andrew McCammon J
Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
[TBL] [Abstract][Full Text] [Related]
9. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
[TBL] [Abstract][Full Text] [Related]
10. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors.
Lee SG; Chmielewski J
Chem Biol; 2006 Apr; 13(4):421-6. PubMed ID: 16632254
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
[TBL] [Abstract][Full Text] [Related]
13. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
14. An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface.
Bannwarth L; Reboud-Ravaux M
Biochem Soc Trans; 2007 Jun; 35(Pt 3):551-4. PubMed ID: 17511649
[TBL] [Abstract][Full Text] [Related]
15. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
16. Dimerization inhibitors of HIV-1 protease.
Boggetto N; Reboud-Ravaux M
Biol Chem; 2002 Sep; 383(9):1321-4. PubMed ID: 12437124
[TBL] [Abstract][Full Text] [Related]
17. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.
Bannwarth L; Kessler A; Pèthe S; Collinet B; Merabet N; Boggetto N; Sicsic S; Reboud-Ravaux M; Ongeri S
J Med Chem; 2006 Jul; 49(15):4657-64. PubMed ID: 16854071
[TBL] [Abstract][Full Text] [Related]
18. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
[TBL] [Abstract][Full Text] [Related]
19. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
[TBL] [Abstract][Full Text] [Related]
20. Oximinoarylsulfonamides as potent HIV protease inhibitors.
Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
